Johnson & Johnson

The 8 mg dexamethasone pre-medication regimen reduced infusion-related reaction (IRR) rates with intravenous amivantamab to 22.5%, a three-fold decrease from historical 67.4% rates.

Pre-medication with dexamethasone reduces infusion-related reaction rate with intravenous RYBREVANT® by three-fold in EGFR-mutated advanced NSCLC patients.

FDA approved amivantamab-vmjw (Rybrevant) plus lazertinib (Lazcluze) for first-line treatment of locally advanced or metastatic EGFR-mutant NSCLC, based on MARIPOSA trial data showing improved median PFS (23.7 months vs 16.6 months with osimertinib). The combination targets EGFR mutations, including exon 19 deletions and exon 21 L858R substitutions, addressing suboptimal responses to current third-generation TKIs. Future research will focus on managing toxicities and developing next-generation therapies.

The Global Monoclonal Antibodies Market is projected to grow from USD 279.8 billion in 2024 to USD 804.7 billion by 2033, at a CAGR of 12.5%. North America is expected to dominate with a 47.5% share in 2024, driven by strong healthcare infrastructure and high R&D investments. Oncology is projected to lead the application segment with a 46.2% share. Major companies include Roche, Novartis, Johnson & Johnson, Pfizer, and Merck.

Johnson & Johnson's Rybrevant and Lazcluze combo showed a 23% OS benefit over AstraZeneca's Tagrisso in advanced non-small cell lung cancer, with 61% survival at three years versus 53%. The combo also reduced CNS disease risk by 18% and received FDA approval for EGFR-mutated NSCLC.

Global Monoclonal Antibodies Market to reach USD 804.7 billion by 2033, growing at a CAGR of 12.5% from USD 279.8 billion in 2024. Dominated by North America, human-derived antibodies, and oncology applications, with key players including Roche, Novartis, and Johnson & Johnson.

The global mRNA vaccine market is projected to decline at a CAGR of -4.3% from 2024 to 2034, reaching US$ 9.6 billion by 2034. Factors driving market growth include streamlined approval processes, innovations in logistics, increasing public trust, and ongoing research into long-term efficacy. Key players include Pfizer-BioNTech, Moderna, and Novartis, with North America leading in market share.

Longer-term MARIPOSA study data show RYBREVANT® plus LAZCLUZE™ provides superior outcomes vs osimertinib in first-line EGFR-mutant advanced NSCLC, with a strong OS trend favoring the combination at 3 years.

The early development of GLP-1 drugs, led by Jeffrey Flier and colleagues, faced abandonment by Pfizer in 1991 due to misconceptions about their potential. Despite promising results, Pfizer's decision to focus on non-injection delivery methods led to the termination of the project. The GLP-1 class eventually achieved significant commercial success, highlighting the complexities and uncertainties in drug development.

Clinical results show Lecraza monotherapy has a progression-free survival (PFS) of 18.5 months, compared to 16.6 months for Tagrisso, with an objective response rate (ORR) of 83% versus 85%. Yuhan Corporation plans to consult with Johnson & Johnson for FDA approval of Lecraza monotherapy, which could potentially exceed $5 billion in annual sales.